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Abstract
The cystine-knot containing protein Sclerostin is an important negative regulator of bone growth and therefore represents a
promising therapeutic target. It exerts its biological task by inhibiting the Wnt (wingless and int1) signaling pathway, which
participates in bone formation by promoting the differentiation of mesenchymal stem cells to osteoblasts. The core
structure of Sclerostin consists of three loops with the first and third loop (Finger 1 and Finger 2) forming a structured b-
sheet and the second loop being unstructured and highly flexible. Biochemical data showed that the flexible loop is
important for binding of Sclerostin to Wnt co-receptors of the low-density lipoprotein related-protein family (LRP), by
interacting with the Wnt co-receptors LRP5 or -6 it inhibits Wnt signaling. To further examine the structural requirements for
Wnt inhibition, we performed an extensive mutational study within all three loops of the Sclerostin core domain involving
single and multiple mutations as well as truncation of important regions. By this approach we could confirm the importance
of the second loop and especially of amino acids Asn92 and Ile94 for binding to LRP6. Based on a Sclerostin variant found in
a Turkish family suffering from Sclerosteosis we generated a Sclerostin mutant with cysteines 84 and 142 exchanged
thereby removing the third disulfide bond of the cystine-knot. This mutant binds to LRP6 with reduced binding affinity and
also exhibits a strongly reduced inhibitory activity against Wnt1 thereby showing that also elements outside the flexible
loop are important for inhibition of Wnt by Sclerostin. Additionally, we examined the effect of the mutations on the
inhibition of two different Wnt proteins, Wnt3a and Wnt1. We could detect clear differences in the inhibition of these
proteins, suggesting that the mechanism by which Sclerostin antagonizes Wnt1 and Wnt3a is fundamentally different.
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Introduction
The human skeleton has about 200 bones forming a very
complex tissue with a multitude of functions. It stabilizes and
protects the inner organs but on the other hand also serves as a
storage pool for the important ions calcium and phosphate. In the
bone marrow important hematopoietic cells such as the erythro-
cytes, the thrombocytes or the T- and B-lymphocytes are formed.
Although bone seems unchanging at first sight, it is not a dead
tissue, but goes through permanent life-long modeling and
remodeling processes not only during upgrowth but also after its
ending i.e. the 2nd decade in life. Damages in bone caused by
mechanical stress are continuously repaired; hormones regulate
the release of calcium and phosphate to replenish blood serum
level by decomposing bones [1]. To execute these tasks a tightly
regulated system of interacting cells is required. Among these are
the ‘‘bone-forming’’ osteoblasts, which buildup the osteoid by
secretion of extracellular matrix [2]. After mineralization, the
osteoblasts differentiate to osteocytes, the master regulators of
bone growth and depletion. A third cell type is the osteoclast,
which is the opponent of the osteoblast and thus is responsible for
dismantling the bone tissue [3].
For the development of the osteoblasts the Bone Morphogenetic
Proteins (BMP) signaling pathway plays an important role [4].
Besides the former also the canonical Wnt (Wingless and Int1)
signaling pathway has been shown to contribute to bone
formation. The signaling strength of the Wnt pathway determines
whether mesenchymal stem cells (MSC) differentiate to either
chondrocytes or osteoblasts with a weak Wnt signal leading to the
formation of chondrocytes and strong Wnt activity resulting in
differentiation to osteoblasts [5]. Deregulation of bone formation
and resorption leads to severe diseases. Defects in bone resorption
due to lower activity in osteoclasts result in osteopetrosis with
patients showing increased bone mass [6]. On the contrary
increased activity in osteoclasts or decreased activity in osteoblasts
leads to a reduction in bone mass. The most prominent disease
showing decreased bone mass is osteoporosis, which affects more
than 30% of women after menopause [7]. The molecular cause is
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e81710
loss of estrogen leading to the increased expression of tumor
necrosis factor (TNF)a, interleukin (IL)-1, macrophage-colony
stimulating factor (M-CSF) and receptor activator on nuclear
factor k-B ligand (RANKL) all of which are positive regulators of
osteoclastogenesis [8,9]. Most current therapeutics target at
osteoclast activity via anti-catabolic mechanisms thereby prevent-
ing further loss of bone mass [10]. The only common osteoana-
bolic option is the application of parathyroid hormone (PTH), an
84 amino acids (aa) peptide hormone, which increases the number
of osteoblasts [11]. However, a very stringent application scheme
is required and PTH overproduction (or application) reverses its
osteoanabolic function [12]. In rats overdosing of PTH has even
led to the formation of osteosarcoma and thus application of PTH
in humans is currently limited to two years [13]. This shows the
strong need for an alternative osteoanabolic therapy to efficiently
target osteoporosis.
Sclerostin, originally identified in genetic screens of two diseases
characterized by strong increased bone mass, Sclerosteosis and van
Buchem syndrome, could provide such a target. Here gene
expression of SOST (encoding Sclerostin) is either lost or blunted
indicating that Sclerostin is a negative regulator of bone formation
and its inhibition might restore normal bone formation rate
[14,15]. Interestingly, small nuclear polymorphism in the regulator
elements of the SOST gene could be linked to predisposition for
osteoporosis [16]. Initially, Sclerostin was described as a direct
high-affinity antagonist of BMP signaling belonging to the DAN
family of BMP modulator proteins [17,18]. It is a secreted 213aa
glycoprotein containing a consensus motif for a cystine-knot, but
outside the cystine-knot motif Sclerostin shares very little sequence
homology with the other DAN family members. The highly bone-
specific phenotype of SOST loss-of-function mutants might be
explained by the fact that osteocytes are the sole source of
Sclerostin [19,20]. Most importantly, Sclerostin seems not to affect
osteoclasts but rather limits the activity of osteoblasts by impeding
proliferation and differentiation of mesenchymal stem cells (MSCs)
to osteoblasts, as well as decreasing mineralization and inducing
apoptosis in osteoblasts [18,21,22]. Although these properties
make Sclerostin a prime target for an osteoanabolic therapy
approach against osteoporosis, little is known about its molecular
mechanism of action. In contrast to previous reports Sclerostin is a
direct modulator/inhibitor of the Wnt signaling pathway and not
an antagonist of extracellular BMPs [23]. Its BMP-inhibiting
activities were shown to rather occur in a cell autonomous manner
by sequestering BMP inside the cell [24]. Like the classical Wnt
inhibitor Dickkopf1 (Dkk1) Sclerostin binds to the Wnt co-receptor
LRP5 or the homologue LRP6 and thereby antagonizes Wnt
activity [25]. Deletion studies showed that the binding site on
LRP5 resides in the first two of the four YWTD b-propeller
domains present in the ectodomain of LRP5 [26]. New findings
revealed that for binding to the first LRP6 b-propeller domains a
NXI amino acid motif common in Wnt-inhibitors like Sclerostin
and Dkk1 is crucial [27]. By performing an extensive mutational
study on the structured part of Sclerostin we could confirm the
importance of the loop including this sequence motif. Furthermore
we could show that apart from this part of the protein also the
cystine-knot is important for Sclerostin activity.
Materials and Methods
Expression of Sclerostin in E.coli
Wildtype and variant proteins of full-length murine Sclerostin
(Sclerostin) were obtained from bacterial expression as described
previously [28]. All proteins were purified by a two-step
chromatography with first performing a cation-exchange chroma-
tography and a subsequent reversed-phase HPLC employing a
0.1% trifluoroacetic acid/acetonitrile gradient to produce homo-
geneous and pure Sclerostin protein. Recombinant proteins were
analysed by SDS-PAGE and ESI-FT ICR mass spectrometry
confirming the theoretical mass and ensuring a purity of greater
than 95%.
Single and double mutants of Sclerostin were generated by site
directed mutagenesis using the Rapid PCR methodology by
Weiner and Costa [29]. For the generation of deletion variants
(Sclerostin DLoop) or Sclerostin variants containing multiple
mutations (Sclerostin Alaloop, Sclerostin F1mut, and Sclerostin
F2mut) cDNAs containing all mutations were obtained by gene
synthesis (Geneart). Expression, refolding and purification of the
Sclerostin variants followed the process described for wildtype
murine Sclerostin [28].
Absorbance of purified wildtype and mutant Sclerostin proteins
at 280 nm was measured and protein concentration was
determined by using extinction factors that were calculated from
the amino acid sequence of the proteins using the software
ProtParam (http://web.expasy.org/protparam; SIB Swiss institute
of bioinformatics).
Production of Sclerostin and hLRP6 E1E2 in FreestyleTM293F-
cells.
The cDNAs encoding for the first two propeller domains of the
human LRP6 (termed LRP6E1E2) as well as for murine Sclerostin
and variants thereof were cloned into the expression vector
pHLsec [30] using the restriction sites for the endonucleases AgeI
and KpnI. The resulting protein constructs consist of an N-terminal
signal peptide for secretion of the protein into the medium and a
C-terminal hexahistidine sequence for metal ion affinity chroma-
tography. FreestyleTM293F-cells were cultivated according to
manufacturer’s recommendation. For transfection in 6-well plates
(Sclerostin and variants thereof) or in 2 L flasks (hLRP6E1E2) cells
were grown to a density of 8.56105 cells/ml. 5 mg DNA and 2 ml
PEI (25 kDa, linear, 1 mg/ml) were used in the transfection
reaction per ml cell suspension. Additionally, for expression of
hLRP6E1E2 2.5 mg vector DNA encoding for the chaperone
MESD were added per ml cell suspension. The PEI-DNA
complex formation was performed in OptiMEM for 20 min at
room temperature. For purification of LRP6E1E2 cell supernatant
was supplemented with 300 mM NaCl and loaded onto a 1 ml
His-TrapTM excel column (GE Healthcare). The resin was washed
with 40 ml buffer (20 mM Tris-HCl, 300 mM NaCl, 20 mM
imidazole, pH 8.0) and then the protein was eluted in 1 ml
fractions (20 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole
pH 8.0). Buffer was exchanged for HBS150 (10 mM Hepes,
150 mM NaCl) by dialysis, the protein was concentrated by
ultrafiltration and supplemented with 50% glycerol for storage at
4uC. The protein concentration was determined as described
above. The Sclerostin proteins derived from eukaryotic cell culture
were used without purification as conditioned medium of the cell
culture supernatant. The concentration of Sclerostin in these
supernatants was determined by Western blot analysis using anti-
His-tag antibodies and comparing the intensities of the protein
bands to those of a concentration series of purified E. coli derived
Sclerostin protein. For a more accurate estimate of the concen-
tration, the blots were scanned and the intensities of the bands
were quantified using the software ImageJ.
Luciferase transcriptional reporter gene assay for measuring
Wnt/b-Catenin signaling.
Cells were cultivated at 37uC and 5% CO2 in DMEM
(Invitrogen) containing 10% (v/v) FCS, 100 U/ml penicillin G,
100 mg/ml streptomycin (Invitrogen). For generation of HEK-
293TSA M50, a stable reporter cell line for quantitative
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measurement of canonical Wnt/b-Catenin activity, HEK-
293TSA cells were seeded in a 6-well plate at a density of
46105 cells/ml. After 24 h cells were transfected with 1.8 mg of
M50 Super 8xTopFlash (provided by Randall Moon) and 200 ng
linearized hygromycin marker DNA (Clontech) using HEKFectin
(Bio-Rad) according to the manufacturer’s protocol. Two days
after transfection cells were transferred to a 6 cm culture plate
(Greiner) and selection of clones was initiated by adding 200 mg/
ml hygromycin. Selection was continued for several rounds and
different pools of stably transfected cells were tested. A cell pool,
which showed a dose-dependent response of the reporter to
recombinant Wnt3a was then selected for further reporter gene
analysis.
For measurement of Wnt3a activity HEK-293TSA M50 cells
were seeded in a 96-well plate at a density of 2.56105 cells/ml.
After 24 h the cells were stimulated using 1.5 nM mWnt3a (R&D
Systems) in the presence of varying concentrations (1 mM-0.2 mM)
of wildtype Sclerostin or variants thereof. The stimulated cells
were lysed after 24 h using 50 ml reporter lysis buffer (Promega)
per well and a single freeze and thaw cycle at 280uC. 20 ml of the
cell lysate were mixed with 50 ml of luciferase assay substrate
(Promega). Luciferase activity was measured using a luminometer
(Luminoscan Ascent, Labsystems). Data analysis was performed
with Prism 5 (Graphpad) using nonlinear regression.
For measurement of Wnt1 activity 15 ml HEK-293TSA M50
cell suspension was seeded in 10 cm culture dishes at a density of
1.56105 cells/ml. After 24 h the cells were transfected with 12 mg
of an expression vector for mWnt1 (mouse cDNA clone
MC205633, Origene) or 12 mg empty vector (pEF6B, Invitrogen)
per well using 0.3 ml Xfect reagent/mg DNA (Clontech). On the
following day cells were seeded to 80% confluency in 96-well
plates. 48 hours after transfection cells were stimulated with
different concentrations of wildtype Sclerostin or mutants thereof.
Stimulated cells were lysed after 24 h using 50 ml reporter lysis
buffer (Promega) per well and a single freeze and thaw cycle at
280uC. Luciferase activities were measured as stated above.
Cellular b-Catenin-Assay
The assay is based on the publication of Hannoush, 2008 [31].
HEK293TSA M50 cells were seeded at a density of 26104 per
well into a D-lysine coated, white, clear bottom 96-well plate
(Greiner). After 12 h cells were stimulated with 4.4 nM recombi-
nant mWnt3a and different concentrations of Sclerostin (4-
0.03 mM) or mDkk1 (20-0.2 nM, R&D Systems). As a positive
control, cells were treated with 50, 25 and 12.5 mM LiCl. After
6 h cells were fixed with 4% paraformaldehyde in medium,
washed three times with PBS and permeabilized 3 times with PBS
containing 0.1% Triton X-100 for 2 minutes. Blocking was
performed over night with Licor blocking buffer MB-070 (Rock-
land). On the next day, after washing with PBS/0.1% Tween 20,
cells were incubated for 1 h with an antibody specific for b-
Catenin (cat# 610154, Beckton Dickinson) diluted 1:200 in
blocking buffer. The plate was incubated for 1 h with a secondary
antibody (1:200, anti-mouse IRDye 800 CW, Rockland) and
Draq5 (0.5 nM, Biostatus). After washing, buffer was removed and
the plate was scanned at 700 and 800 nm (Odyssey, Licor). Data
analysis was performed as described [31].
For analysis upon Wnt1 stimulation, 26106 HEK293TSA M50
cells were seeded in 15 ml medium in 10 cm cell culture dishes
and transfected with 12 mg pCMV6-Kan/Neo expression vector
encoding for mWnt1 (mouse cDNA clone MC205633, Origene) or
empty vector (pEF6B, Invitrogen) using 3.6 ml Xfect reagent
(Clontech). After 12 h incubation the cells were seeded to 90%
confluency in 96-well plates. 24 h later cells were treated with
different concentrations of Sclerostin (133-0.5 nM) and mDkk1
(13-0.05 nM, R&D Systems) for 4 h. Cells transfected with empty
vector were treated with 33, 17 and 8 mM LiCl. Immunodetec-
tion, staining and data analysis were performed as indicated
above.
Radioligand binding assay for binding of Sclerostin to
LRP6
Iodination of proteins followed a protocol adapted from the
method by Frolik et al. [32]. For iodination of Sclerostin or the
variants 1 mg protein was dissolved in 13 ml 2 M sodium
phosphate buffer pH 7.5. The protein was incubated with 5 ml
of Na125I (18MBq, Perkin Elmer) and 5 ml of Chloramine T
(100 mg/ml) for 2 minutes. Another 5 ml Chloramine T were
added two more times followed by 2 minutes incubation steps
each. The reaction was stopped by adding 20 ml N-acetyl tyrosine
(50 mM), 20 ml potassium iodide (60 mM) and 200 ml urea (1.2 g
in 1 ml water) in 1 M acetic acid and incubation of this mixture
for 2 minutes. The proteins were separated from non-reacted
iodine using a G25 (PD-10) size exclusion column equilibrated
with column buffer (75 mM NaCl, 4 mM HCl, 1 mg/ml BSA).
Fractions containing 125I-radiolabeled protein were pooled and
used immediately or stored at 4uC until further use.
For the crosslinking assay COS1 cells were seeded in 10 cm
dishes in DMEM containing 10% (v/v) FCS at 75% confluency
and transfected the next day using linear PEI 25 kDa and 10 mg of
the LRP6 expression plasmid (derived from pCS2 LRP6-EGFP,
gift from C. Niehrs, DKFZ Heidelberg, Germany). Cells were
transferred to 6 well plates after 24 h. The next day cells were
washed twice with PBS-B (PBS, 0.91mM CaCl2, 0.49 mM MgCl2)
plus 1 mg/ml BSA, before they were incubated on ice for 2 h with
10 ml 125I-labeled wildtype or mutant Sclerostin protein (1 nM) in
0.5 ml PBS-B plus 1 mg/ml BSA. Unlabelled protein was added
for competition where indicated. After incubation the cells were
washed with PBS-B and crosslinking was performed by incubation
for 15 minutes in PBS-B on ice using 0.27 mM disuccinimidyl
suberate (DSS) and 0.07 mM bis(sulfosuccinimidyl)-suberate (BS3).
Then cells were washed with detachment buffer (10 mM Tris-
HCl, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl-
fluoride (PMSF), pH 7.4) and scraped off in 150 ml detachment
buffer. The suspension was centrifuged for 2 min at 18.0006g and
cells were lysed by adding 500 ml solubilisation buffer (10 mM
Tris-HCl, 125 mM NaCl, 1 mM EDTA, 1% Triton A-100,
pH 7.4) containing a protease inhibitors cocktail mix (PMSF,
Aprotinin, Leupeptin (Roche) and incubated on ice for 30
minutes. Debris was removed by centrifugation at 18.0006g for
2 min and protein concentration was determined by performing a
Lowry assay (DC Protein Assay, Biorad). For quantification of
Sclerostin bound to LRP6 equal amounts of protein were loaded
on a SDS-PAGE gel and the electrophoresis was performed over
night (7 mA, RT). After fixing and drying, the gel was analysed
using a Phosphoimager (STORM imaging system, Amersham
Biosciences). Bands were quantified using ImageJ.
Binding analysis of the Sclerostin-LRP6 interaction using
a Pull Down assay
Purified Sclerostin proteins were biotinylated using EZ-Link
Sulfo-NHS-LC-Biotin (Thermo Scientific) in a molar ratio of 1:1.5
in PBS for 1 h at room temperature and overnight at 4uC. For
performing the pull down 1 mM purified human LRP6 was
incubated for 1 hour at 4uC with 225 nM biotinylated Sclerostin
wildtype, DLoop or C84AC142R in 500 ml HBS300T (20 mM
HEPES, 300 mM NaCl, 0.05% Tween-20). The samples were
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then mixed and incubated for 1 hour with 40 ml Streptavidin
Agarose Beads (Novagen). The beads were centrifuged for 2 min
at 20006g, washed three times with 500 ml HBS300T and finally
resuspended in 40 ml SDS-sample-buffer and boiled for 5 minutes
at 95uC. Samples of the beads together with samples from the
initial reaction mixture (input) were subjected to SDS-PAGE and a
subsequent Western-Blot using an antibody recognizing the His6-
tag present in the recombinant Sclerostin and LRP6 proteins
(Penta His HRP conjucate, 5-Prime).
Interaction analysis using Surface Plasmon resonance
Interaction analysis was performed as described elsewhere using
the ProteOnTM XPR36 SPR system (BioRad) [33]. HBS150T
(10 mM HEPES, 150 mM NaCl, pH 7.5, 0.005% Tween20) was
used as running buffer. Sclerostin wildtype or the DLoop variant
proteins were immobilized on separate flow channels at a density
of 600RU on the surface of a ProteOnTM GLC sensor chip
(BioRad). All measurements were performed at 25uC. Interaction
with the antibody Fab fragment was measured by injecting 6
different concentrations (100, 75, 50, 25, 12.5 and 6.25 nM in
HBS150T) for 200 sec using the single shot kinetic setup.
Dissociation data was obtained from subsequent perfusion of the
biosensor with running buffer for 250 sec. For analysis of the
kinetics the data was fitted employing a Langmuir 1:1 interaction
type model using the software ProteOnTM Manager 3.0 (BioRad).
Results
Mutational study on Sclerostin
Previous analyses have shown that the structured cystine-knot
motif contains almost completely the Wnt-neutralizing activity of
Sclerostin [28], the flexible and disordered N- and C-termini seem
not to contribute significantly to inhibition of Wnt3a-mediated
reporter gene expression as measured with the TCF/LEF reporter
construct M50 8xSuperTOPFlash provided by Randall Moon
[34]. We thus focused in our mutagenesis study on positions
located within the cystine-knot core but used full-length murine
Sclerostin for the analysis. From mutations in the Wnt co-receptor
LRP5 found in human patients with a bone-overgrowth pheno-
type (high-bone mass or HBM) resembling that of the Sclerostin
null mutations the Sclerostin binding site was proposed to be
localized in the first b-propeller domain of LRP5 [35,36,37,38,39].
This epitope was later confirmed by deletion studies of LRP5,
showing that Sclerostin-mediated Wnt3a inhibition depends on
the presence of the first two b-propeller domains [26]. Since both
proteins exhibit a highly complimentary charge distribution [28]
we opted to mutate first 9 out of 16 arginine residues present in the
core region of murine Sclerostin between Asn38 and Arg118 to
alanine (Fig. 1A and B). The NMR mapping studies of a
Sclerostin-neutralizing antibody reported by Veverka et al.
reported for the first time that the Wnt-inhibitor activity of
Sclerostin is likely confined in the flexible loop region of Sclerostin
[40] (Fig. 1C). A Fab fragment raised against murine Sclerostin,
which efficiently neutralizes Sclerostin-activity [41], also binds to
the flexible loop region as determined by NMR (Boschert, V.,
Frisch, C., Schmieder, P., Mueller, T.D., manuscript in prepara-
tion) thereby highlighting the importance of the loop region for
activity. Conformingly a recent crystallographic study showed a
complex of a 7 mer peptide mimicking the Sclerostin loop residues
Leu90 to Arg96 bound to propeller 1 of LRP6 [27]. We thus also
targeted the flexible loop more specifically and introduced multiple
mutations in the loop region of Sclerostin (Fig. 1D and E). For the
generation of multi-variants we applied two approaches, first the
loop residues from Leu90 to Asn103 of murine Sclerostin were
deleted and replaced by a two-residue long linker Gly-Ser (termed
DLoop, Fig. 1E). The second approach employed multiple
mutations in the loop to completely alter the potential binding
epitope. Residues Leu90 to Asn103 were therefore exchanged
from the original sequence -LPNAIGRVKWWRPN- to -SPGAS-
GARSGSAPA- (termed Alaloop, Fig. 1D). To test that these loop-
altering mutations did not affect the fold of murine Sclerostin we
tested the binding of Sclerostin DLoop to Fab antibodies directed
against finger 1 obtained from phage display selection and a
directed panning approach using folded peptides mimicking finger
1. These Fab fragments only bind effectively to the oxidatively
folded peptide and not to the corresponding linear form. Thus the
Fab antibodies recognize a non-linear conformational epitope and
can be used as folding indicators for Sclerostin (Back et al., 2012).
In vitro interaction analysis shows that affinities and kinetics for
the binding of wildtype Sclerostin and the variant DLoop to these
Fabs are identical (Fig. S1A). These results clearly indicate that
mutations in the loop of Sclerostin introduced in the variants
DLoop and Alaloop did not affect folding of the finger 1/2 core
structure. To analyze the effect of individual residue mutation on
Sclerostin activity we also performed an alanine scanning
approach for most loop residues except for proline 86 and 91,
which were substituted for aspartate (Fig. 1A and B, in green).
As no clear picture is yet available for the requirement of
residues outside the loop segment of Sclerostin, we similarly used
multiple amino acid exchanges combined in a single multi-variant
to determine whether elements of finger 1 or finger 2 are involved
in Wnt inhibition. For the design of these variants, the structure of
murine Sclerostin was used and non-glycine, non-proline residues,
which are located at the solvent-accessible surface, were selected
for mutagenesis. To avoid refolding problems or decreased
solubility, the selected residues were not exchanged uniformly
against alanine but rather by an approach in which charged
residues were usually substituted for polar but uncharged, and
large amino acids were exchanged to smaller ones and vice versa
unless in silico simulations indicated possible folding difficulties.
Hence in the variant termed mSOST F1mut eight residues in the
Finger1 region (R56N, E57A, H59R, T61K, R62K, T65N,
R70T, K73Q, Fig. 2F), in the variant termed mSOST F2mut nine
surface-located residues in Finger2 (D112A, R113K, R115Q,
R118N, Q120K, R130N, R132Y, K133R, R135T, Fig. 1G) were
exchanged accordingly.
A naturally occurring Sclerostin variant, in which residue
Cys142 - the sixth cysteine of the cystine-knot - is mutated to
arginine, was found in a Turkish family suffering from Scler-
osteosis [42]. It was proposed that due to the importance of an
intact cystine-knot, the exchange of Cys142 to arginine might
disrupt folding of the flexible loop containing the LRP5 binding
epitope and thereby (indirectly) lowers Sclerostin neutralization
activity. The activity of this mutant has so far only been
investigated by analyzing conditioned supernatant of transfected
mammalian cells. These experiments, however, show that the
mutant protein is only poorly secreted, possibly indicating that the
Sclerosteosis in the patients might be due to a Sclerostin dosage
effect. To test irrespectively of the cause of Sclerosteosis in these
patients whether the cystine-knot is functionally important for
Sclerostin activity and LRP6 binding, we first prepared a
Sclerostin variant with Cys142 mutated to alanine employing
our bacterial expression system. However, by performing mass
spectrometry of the purified protein we found that the SH-group
of the Cys142 partner Cys84 is not as expected in its free thiol-
protonated form but is protected by a glutathione moiety
originating from the refolding procedure. As this large tripeptide
group attached to Cys84 possibly interferes with Sclerostin activity
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by an unknown mechanism, we therefore additionally prepared
the double variant C84AC142R containing no free SH-group.
Sclerostin’s NXI-motif and parts of the cystine-knot are
required for inhibition of Wnt1
Sclerostin-mediated inhibition of Wnt1 activity was determined
using a stably transfected reporter cell line developed in house, in
which the reporter-driven expression of luciferase is stimulated by
coexpression of Wnt1. Using this reporter cell line we determined
a concentration for half-maximal Wnt1-inhibition (IC50) by
wildtype Sclerostin of 10.066.9 nM (Fig. 2). Using Wnt1 as a
stimulant all arginine-to-alanine variants exhibited IC50 values
similar to wildtype Sclerostin (Fig. 2A). Deletion or exchange of
the loop region (DLoop and Alaloop Sclerostin, respectively,
Fig. 1C–E), however, resulted in a more than 80-fold increased
IC50 for the inhibition of Wnt1 (Fig. 2A, C, IC50 DLoop
8066426 nM, IC50 Alaloop 8316213 nM). This finding is
consistent data recently reported by Holdsworth et al. [43] and
the observation that a 7 mer peptide mimicking the loop residues
Leu90 to Arg96 binds to the propeller 1 of LRP5 thereby likely
competing for Wnt1 binding [27]. Analysis of the effect of
Sclerostin single amino acid mutants on Wnt1 activity also
revealed individual residues important for mediating inhibition
(Fig. 2A). Two positions important for Sclerostin bioactivity have
been recently reported in two other studies [27,43]. One residue is
Ile94, which showed a strong reduction of Sclerostin-mediated
Wnt1 inhibition when mutated to non-conserved polar or charged
amino acid types [27,43]. However, when we mutated Ile94 to
alanine and thus only removed the hydrophobic side chain
functionality, we observed only a very small reduction in
bioactivity (Fig. 2A,B) (IC50 26.9619.3 nM). Similarly, an
exchange of Ile94 by slightly smaller valine as reported by
Figure 1. Overview of investigated Sclerostin variants. (A) Surface and secondary structure representation of Sclerostin with residues selected
for single point mutations shown as spheres. Residues located in the flexible loop of Sclerostin are colored green, amino acid residues in finger 1 and
2 are indicated in red and magenta, cysteine residues are shown in yellow, respectively. (B) As in (A) but rotated around the y-axis by 180u. (C)
Detailed view of the loop region of Sclerostin comprising the residues Gly85 to Asp106. The backbone atoms are shown as ribbon, side chains of non-
glycine residues as ball-and-stick models. The region consisting of Leu90 to Asn103 used in the mutational analysis is marked with carbon atoms
colored in cyan. (D) Loop region of the Sclerostin multivariant Alaloop. (E) Loop region of the Sclerostin truncation variant DLoop, residues Leu90 to
Asn103 were replaced by a glycine-serine linker. (F) View of the finger region of wildtype Sclerostin and the Sclerostin multivariant F1mut. Residues
shown as ball-and-stick models (carbon atoms colored in red) in finger 1 of wildtype Sclerostin were exchanged to those shown on the left panel. (G)
Residues in finger 2 of Sclerostin and their counterpart in the Sclerostin multivariant F2mut are indicated as ball-and-stick models with the carbon
atoms colored in magenta.
doi:10.1371/journal.pone.0081710.g001
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Figure 2. Reporter gene assay to measure the neutralization of mWnt1 activity by wildtype and Sclerostin variants. HEK293TSA cells
stably transfected with the Wnt-responsive luciferase reporter construct SuperTOPFlash were transfected with an expression construct for murine
Wnt1. After 48 h the cells were stimulated with serial dilutions of wildtype (WT) Sclerostin or variants thereof. (A) Overview of the efficiency of the
Sclerostin proteins to neutralize Wnt1 driven luciferase expression (IC50 values are shown as bar diagram). The right panel shows a magnification of
the data shown in the left panel. Data represents means with standard deviations (SD) of at least three independent experiments. *: P,0.05, **:
P,0.01, ***: P,0.001 (student’s t-test with data obtained for WT Sclerostin). (B–D) Measurements showing the dose-dependency of selected mutant
Sclerostin proteins. IC50 values of these experiments are included in the overview shown in (A). Measurements were done in duplicate. (E) Reporter
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Holdsworth et al. resulted in a minor loss in Sclerostin’s bioactivity
[43]. In our alanine-scanning approach for Sclerostin, the largest
effect on Wnt1 inhibition is seen for the variant N92A, whose
efficiency to inhibit Wnt1 is decreased nearly 20-fold (IC50
195.76110.1 nM, compared to 10.066.9 nM for wildtype
Sclerostin). Holdsworth et al. showed that mutation of Asn92 to
any other amino acids disrupts Sclerostin’s inhibitory activity,
whereas mutation of Ile94 requires a more disrupting non-
conservative exchange [43], confirming our analysis that Asn92
presents the hot spot for the Wnt1 inhibitory activity of Sclerostin.
Given the high affinity of Sclerostin for LRP6 [27], the
assumption of Asn92 and Ile94 representing the whole epitope of
Sclerostin for interacting with LRP5/6 and thereby competing for
binding of Wnt1 to LRP6 seemed unreasonable at first sight. We
thus investigated whether regions outside the loop also contribute
to Sclerostin’s activity. However, analysis of both Sclerostin
variants containing multiple mutations in the two finger regions
shows that the fingers are dispensable for inhibiting Wnt1
(Fig. 2A,D). Both multi-variants F1mut and F2mut showed an
inhibitory activity comparable to wildtype Sclerostin with an IC50
value of 18.866.9 nM for F1mut and an IC50 value of
15.0611.5 nM for F2mut.
To find out whether elements of or residues within the cystine-
knot are important for inhibition of Wnt1, we expressed a double
variant containing the original mutation C142R and C84A. The
additional mutation C84A was implemented to avoid low
secretion yield as found for the single mutant C142R [42].
Indeed, C84AC142R exhibits a 10-fold decreased efficiency to
inhibit Wnt1 activity (Fig. 2E), indicating that mutations outside
the NXI-motif can affect Sclerostin activity. Consistent with the
attenuated inhibition of Wnt1 seen in the Wnt-reporter assay a
decreased binding to the first two propeller of LRP6 (LRP6E1E2)
was observed in a pulldown experiment (see also Fig. 4C, Fig.
S2B). Although the mutation of Cys142 to arginine and
consequently the disruption of the third disulfide bond of the
cystine-knot might affect Sclerostin’s Wnt1 inhibition indirectly by
changing the loop conformation, this is unlikely because of the
highly flexible nature of the loop.
Sclerostin can inhibit Wnt3a by a mechanism different
from Wnt1 inhibition
The ability of Sclerostin to inhibit signaling initiated by Wnt3a
might be questioned by the finding that Sclerostin and Wnt3a bind
to different seemingly non-overlapping regions in the LRP6
receptor ectodomain [26]. Whereas Wnt3a binds to the third and
fourth propeller domain, Sclerostin binds, like Wnt1 (and other
members of the Wnt1 class), to the first and second propeller
domains [44]. Therefore according to this data a competitive
inhibition mechanism should only be possible between Wnt1 and
Sclerostin, as both proteins bind to the same or at least a highly
overlapping site at LRP6. For Wnt3a and Sclerostin Li et al. and
Bourhis et al. could show that Sclerostin and Wnt3a can
simultaneously bind to LRP6 without affecting their interaction
with LRP6 making a competitive inhibition mechanism implau-
sible [26,27]. Several reports nevertheless showed that Sclerostin
could attenuate Wnt3a activity [24,26,28,40,45], although the
required concentrations to efficiently antagonize Wnt3a question
the physiological relevance of Sclerostin as Wnt3a inhibitor. Our
data and others [40] shows that inhibition of Wnt3a by
recombinant Sclerostin (IC50 246667 nM) requires a more than
100-fold higher Sclerostin concentration compared to that
necessary for half-maximal inhibition of Wnt1 (Fig. 3A). Further-
more the Hill coefficient of the dose-dependent inhibition of
Wnt3a by Sclerostin clearly deviates from the expected slope being
a further hint that the inhibition of Wnt3a by Sclerostin follows a
different mechanism than Wnt1 (Fig. 3A). However, the Scler-
ostin-neutralizing Fab antibody AbD09097 [41] rescues Scleros-
tin-mediated Wnt3a inhibition (Fig. 3B). Together with the
variants DLoop and Alaloop of Sclerostin showing a 2.6- and
4.5-fold lower efficiency to antagonize Wnt3a (IC50 DLoop
6556143 nM, IC50 Alaloop 11146475 nM, Fig. 3C) these
observations suggest that the inhibition of Wnt3a by Sclerostin is
specific. Thus although Sclerostin is possibly not a physiological
inhibitor of Wnt3a in contrast to the classical Wnt antagonist
Dkk1, it is mechanistically highly interesting how Sclerostin can
interfere with LRP6 activation by Wnt3a. Despite the small
differences for Wnt3a inhibition observed between wildtype
Sclerostin and the loop-variants DLoop and Alaloop we analyzed
the effect of our set of Sclerostin variants on Wnt3a activity using
our reporter cell line. For almost all single amino acid variants the
changes in the IC50 values were too small and thus statistically not
significant (Fig. 3E). Even for the variant N92A, which showed a
200-fold decreased Wnt1 inhibition no differences could be
observed compared to the wildtype protein. Interestingly, two
mutants, the single residue variant R118A (located in Finger 2)
and the multi-variant F2mut with an altered Finger 2 showed a
small but statistically significant increase in the IC50 values
compared to wildtype Sclerostin (IC50 R118A 606674 nM; IC50
F2mut 6826177 nM, Fig. 3E, Fig. S1B). As alteration in the
Finger 2 of Sclerostin showed no effect on Wnt1 inhibition this
observation presents a further hint that mechanistically Sclerostin
interferes with Wnt1 and Wnt3a activity by a different mechanism.
To get further insights into the different inhibition mechanism
we analyzed the intracellular concentration of b-Catenin. A
hallmark of canonical Wnt signaling is the accumulation of b-
Catenin in the cytoplasm of the cell, where in the absence of Wnt
factors a complex consisting of Axin, GSK3 and APC phosphor-
ylates b-Catenin leading to its proteasomal degradation [46].
When we investigated b-Catenin degradation by quantitatively
measuring the b-Catenin level in cells using a published assay [31],
b-Catenin was decreased in a dose dependent manner by
Sclerostin in cells stimulated with Wnt1 as expected and consistent
with the findings of the reporter-gene analysis (Fig. 3A and D).
However, when we analyzed Sclerostin-treated cells stimulated
with Wnt3a, the b-Catenin level first remains constant and then
even rises with high concentrations of Sclerostin (Fig. 3D),
although these Sclerostin concentrations clearly attenuated the
luciferase reporter-gene expression in our reporter cell line
utilizing a b-Catenin dependent promoter (see also Fig. 3A). To
test whether this surprising result might be specifically related to
Wnt3a, we tested the classical Wnt antagonist Dkk1, which was
shown to bind simultaneously to the first two and the last two
propeller domains of LRP6 and thus can competitively inhibit
Wnt factors of the Wnt1 as well as the Wnt3a subclass [44]. In
contrast to Sclerostin, Dickkopf1 decreases intracellular b-Catenin
levels in a dose dependent manner independent of the Wnt factor
used for stimulation and thus shows that a competitive Wnt
inhibition mechanism leads to a cytoplasmic decrease in b-Catenin
as expected (Fig. 3D). Thus Sclerostin and Dickkopf1 clearly
antagonize Wnt3a through a differing mechanism, how Sclerostin
gene assay using supernatants of HEK Freestyle cells expressing Sclerostin mutants C84AC142R, DLoop or wildtype Sclerostin. Data points represent
duplicates. To highlight the location of the mutation in the Sclerostin structure the same color-coding as in Figure 1 is used.
doi:10.1371/journal.pone.0081710.g002
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Figure 3. Inhibition of Wnt3a signaling by Sclerostin. (A) HEK293TSA cells stably transfected with the Wnt-responsible luciferase reporter
construct SuperTOPFlash were stimulated with 1.5 nM recombinant murine Wnt3a and serial dilutions of murine Sclerostin. Shown is the resulting
dose response curve in comparison to the dose response curve of mWnt1-transfected cells as shown in figure 3. (B) mWnt3a-derived luciferase signal
obtained in presence of Sclerostin wildtype (WT) and 2 mM Sclerostin specific antibody AbD09097 (AbD) or with WT alone. (C) Reporter gene assay as
depicted in (A) and (B) showing the dose-dependency of Sclerostin Alaloop and DLoop in comparison to WT Sclerostin. Measurements were done in
duplicate. (D) Measurement of the intracellular level of b-Catenin upon mWnt3a and mWnt1 stimulation in presence of Sclerostin or Dkk1 using In-
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can decrease gene transcription driven from a b-Catenin promoter
(see Fig. 3A) when it does not alter b-Catenin levels has to be
subject for further studies.
Binding of Sclerostin to LRP6 is usually required for Wnt
inhibition
The Wnt-inhibiting activity of Sclerostin has previously been
linked to its ability to bind to LRP co-receptors [26,39]. As
reduced LRP-binding of Sclerostin loop mutants was so far shown
exclusively by in vitro interaction analysis using the isolated
binding partners we wanted to examine the binding properties of
our variant proteins in their cellular surrounding. We therefore
performed a competition binding experiment using COS1 cells
overexpressing human LRP6 and incubating them with 125I-
labeled wildtype Sclerostin in presence or absence of unlabeled
mutant proteins. The Sclerostin proteins were then crosslinked to
the co-receptor LRP6 using disuccinimidyl suberate (DSS) and
bis(sulfosuccinimidyl) suberate (BS3) and cell lysates were subse-
quently separated by SDS-PAGE. Without addition of an excess of
unlabeled wildtype protein to compete off the radiolabeled
Sclerostin from its receptor LRP6 we observed a prominent band
in the autoradiography. This band was only visible in cells
transfected with human LRP6 and therefore clearly corresponds to
wildtype Sclerostin crosslinked to the extracellular domain of
LRP6 (Fig. 4A, marked w/o). This band diminished when an
excess (100-fold) of unlabeled wildtype Sclerostin was added
(Fig. 4A, marked WT). Most Sclerostin variants showed compe-
tition efficiency similar to wildtype protein, except for the
Sclerostin variants Alaloop and DLoop (Fig. 4A), as can also be
seen in a summary showing the normalized results of several
experiments (Fig. 4B). Since the latter mutants did not compete
with the radiolabeled wildtype protein, they either do not bind at
all or only with greatly diminished affinity to the extracellular
domain of LRP6. To exclude the possibility that the radiolabeling
interferes with the ability for competition, we repeated the
experiment but using radiolabeled variant proteins. Iodination of
Sclerostin DLoop and Alaloop showed that both loop variants do
indeed not bind to LRP6 with high affinity as even with no
competitor present only a faint band of the crosslinked product
could be observed (Fig. S2A). Thus for the two Sclerostin loop
variants the loss of LRP6 binding directly correlates with their lack
of inhibiting Wnt1 or Wnt3a in the reporter gene assay and
underlines the importance of the loop for Sclerostin activity and
binding to LRP6. Consistently, also the single amino acid
mutation of the loop residues Asp92 or Ile94 to alanine had a
significant effect on binding to LRP6 albeit slightly smaller than
what was observed for the variants DLoop and Alaloop (Fig. 4A,B).
So possibly the slightly higher affinity for LRP6 of the two single
residue mutants resulted in the stronger inhibition of Wnt3a
activity (Fig. 3E), whereas they could not completely inhibit Wnt1
activity (Fig. 2A). Thus so far all loop mutants that were tested and
show decreased affinity for LRP6 also exhibit a lower Wnt1
inhibition efficiency in line with the hypothesis that LRP6 binding
and Wnt inhibition is correlated in Sclerostin.
This hypothesis seems also true for the variant C84AC142R
affecting the cystine-knot. For the interaction analysis recombinant
LRP6E1E2 protein was incubated with purified Sclerostin or
variant proteins that were biotinylated in a 1:1.5 stoichiometry
using an NHS-activated biotin. After pull-down of the Sclerostin
proteins via Streptavidin agarose the Sclerostin:LRP6 complex
was probed with an antibody against the hexahistidine tag, which
are present at the N-terminus of Sclerostin and at the C-terminus
of LRP6E1E2 (Fig. 4C). Consistent with the radioligand binding
assay wildtype Sclerostin is bound to LRP6E1E2, whereas the
variant DLoop lacking residues Leu90 to Asn103 does not bind
LRP6. For the cysteine variant C84AC142R, the Western Blot
reveals a faint, but at longer exposure times clearly visible band
thereby indicating that mutation of the third disulfide bond and
introducing an arginine residue for Cys142 weakens binding to
LRP6 (Fig. 4C, Fig. S2B). This suggests that the cystine-knot is
likely also part of the Sclerostin epitope for binding to LRP6 and
that the LRP5/6 binding site on Sclerostin contains additional
elements in addition to the NXI-motif observed by Bourhis et al.
[27]. Furthermore, all Sclerostin mutations that were tested and
showed an attenuated inhibition of Wnt1 also exhibit decreased
binding affinity for LRP6 indicating that LRP6 binding and Wnt1
inhibition is likely directly related.
However, in the analysis of Sclerostin residues affecting
inhibition of Wnt3a two more mutants were identified, the
Sclerostin variant R118A and the multi-variant F2mut (Fig. 3E,
Fig. S1B). Both mutants show a significant reduction in the ability
to inhibit Wnt3a-mediated reporter-gene expression, but do not
affect inhibition of Wnt1 activity. As the residues exchanged in
both variants are located in Finger 2 of Sclerostin and are thus
structurally far remote from the LRP6 main binding determinant
the NXI-motif (Fig. 1), it was unclear whether elements in Finger 2
play a role in LRP binding. Using the radioligand-binding assay
on whole cells, the ability of these two mutants to compete with
wildtype radiolabeled Sclerostin was tested. As both variants
clearly replace the radiolabeled wildtype Sclerostin from its
complex with LRP6 their binding to LRP6 seems unaltered
(Fig. 4A,B; Fig. S2A). This presents a further hint that Sclerostin-
mediated inhibition of Wnt3a occurs via an unknown non-
competitive mechanism.
Discussion
The role and impact of Wnt signaling in cancer is long known
since the discovery that the integration of the mouse mammary
tumor virus (MMTV) into the Wnt1a locus (int1) is the driver of
virus-induced oncogenesis [47]. Besides its role in cancer biology
Wnt signaling has gained great medical interest due to its
involvement in bone homeostasis, initially discovered through
gain- or loss-of-function mutations in the Wnt co-receptor LRP5
leading to either a high-bone mass phenotype or low bone density
[36,38,48]. In this context, the Wnt inhibitors of the Dickkopf
family and Sclerostin have received special attention, as both of
them lead to bone loss by negatively regulating Wnt activity.
Sclerostin was discovered from genetic screenings of patients
showing increased bone densities, revealing that patients suffering
from van Buchem disease or Sclerosteosis lack or have decreased
levels of Sclerostin [14,19]. Sclerostin’s exclusive expression in
bone by osteocytes [18] and the absence of any other phenotype
Cell Western. The fluorescence signal determined from the antibody against b-Catenin was normalized for cell number using DNA staining with
DRAQ5. Signal of non-transfected/untreated cells was set to 0% and signal of cells treated/transfected with Wnt proteins alone was set to 100%. A
typical experiment out of three is shown; datapoints represent means with SD of two independent measurements. (E) Overview of the efficiency of
Sclerostin WT and mutant proteins to neutralize Wnt3a driven luciferase expression (IC50 values represented as bar diagram). Data represent means
with standard deviation (SD) of at least two independent experiments. *: P,0.05 **: P,0.01 (student’s t-test with data obtained for wildtype
Sclerostin). To highlight the location of the mutation in the Sclerostin structure the same color-coding as in figure 2 is used.
doi:10.1371/journal.pone.0081710.g003
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other than increased bone density in the Sclerostin knockout mice
[49] make Sclerostin a perfect target for osteoanabolic treatments.
This led to a number of recent studies utilizing Sclerostin-
neutralizing antibodies in animals [50,51,52] and humans [53,54]
showing that neutralization of Sclerostin can restore bone density
in osteoporosis models [50] or other conditions resulting in bone
loss [55,56,57,58,59].
Mechanistically, Sclerostin as well as members of the Dickkopf
family inhibit canonical Wnt/b-Catenin signaling by binding to
the Wnt co-receptors LRP5 or LRP6, however the binding sites on
the large extracellular domain differ. Structural and functional
studies revealed that the modular two-domain Dkk1 binds to the
first and third of the four propeller domains of LRP5/6 (on the
basis of the four propeller domains full-length extracellular LRP6
will be termed LRP6E1E4)) [26,27,44,60,61,62,63]. In contrast
Sclerostin binds only to the first or the first two propeller domains
of LRP6 (termed LRP6E1E2) as no measurable interaction was
detected to a LRP6 deletion fragment comprising only propeller 3
and 4 (termed LRP6E3E4) [26,27]. Consistently, mutations
leading to a high-bone mass (HBM) phenotype and located in
the first propeller domain of LRP5 only disrupt binding to
Sclerostin whereas binding of Dkk1 seems unaffected [39]. Recent
structure analyses of LRP6NDkk1 interactions support this view.
Here, the C-terminal cysteine-rich domain of Dkk1 engages tightly
with an LRP6E3E4 fragment [60,62], whereas a short peptide
derived from the Dkk1 N-terminus (residues Asn7 to Asn13 of
mature Dkk1) binds to the propeller 1 of LRP6 [27] (see also
Fig. 5A). This explains the binding cooperativity seen in
interaction analyses utilizing full-length or fragments of Dkk1
and LRP6. Full-length Dkk1 binds to the LRP6 fragments
LRP6E1E2 and LRP6E3E4 with an affinity of 50 to 70 nM,
whereas binding to full-length LRP6 occurs with very high affinity
[44,60].
In contrast to the data for Dkk1, structural analysis of the
binding of Sclerostin to propeller 1 of LRP6 is so far limited to a
short 7 mer peptide sequence homologous between Dkk1 and
Sclerostin sharing a so-called NXI-motif (Fig. 5A) [27]. In
Sclerostin the NXI-motif is located in the tip of the dynamic
loop. Analyses of Bourhis et al. and Holdsworth et al. have so far
identified two main binding determinants for binding of Sclerostin
to LRP6 [27,43]. One, the conserved asparagine residue engages
in five hydrogen bonds, three of which emanate from its
carboxamide side chain (Fig. 5A) [27]. Two further hydrogen
bonds involve the backbone carbonyl of the NXI-asparagine. The
corresponding co-receptor residues are invariant in LRP5/6 and
are part of the HBM mutations [27]. The other determinant of the
NXI-motif, the isoleucine residue, deeply immerses into a
hydrophobic pocket built by various conserved residues in
LRP6, which again are either part of the HBM mutations or are
in close proximity to known HBM mutations (Fig. 5A) [27].
Noteworthy, almost all the co-receptor key residues are also
conserved in LRP4, which has been identified as a co-receptor for
Sclerostin and Dkk1 [64]. Furthermore, most interacting residues
of LRP6 are also found in LDLR, which does not bind Sclerostin
[25]. However, whereas coordination of the NXI-asparagine
might be accomplished as in LRP5/6, the hydrophobic cleft for
the NXI-isoleucine residue differs between LRP and LDLR
suggesting that both residues in the motif are equally important for
recognition of the Wnt modulator proteins (Fig. S3).
Most importantly, the small epitope of the 7 mer peptide in the
LRP6-peptide complex seems insufficient to account for the high-
affinity interaction of Sclerostin to LRP6, which was determined at
about 10 nM for the binding to LRPE1E4 or LRP6E1E2 [27].
Indeed, the large excess of peptides required to crystallize the
Figure 4. Analysis of binding of wildtype Sclerostin and
different variants to hLRP6. (A) COS-1 cells were either transfected
with an expression construct encoding for hLRP6 (COS-1 + hLRP6) or
mock-transfected using empty vector (COS1). Cells were then incubated
with I125-labeled wildtype Sclerostin (I125). Protein bound to the cell
surface was chemically crosslinked in the presence of 2 mg unlabeled
wildtype Sclerostin or the indicated Sclerostin variants for competition,
corresponding to a 100-fold excess of unlabeled protein. The
radioactivity bound to the cells was subsequently analyzed by
autoradiography. Shown bands were all obtained in the same
experiment. The black bar indicates that the picture was cut to omit
samples that are not relevant for this publication. (B) Quantitative
autoradiography analysis of several experiments as shown in (A). All
bars were normalized by setting the intensity of the protein band
obtained from addition of unlabeled wildtype Sclerostin to partially
compete off I125-labeled wildtype Sclerostin to 1. Data represent means
with standard deviations (SD) of at least three independent experi-
ments. *: P,0.05, **: P,0.01 (student’s t-test with data obtained for
variant R56A). (C) Western Blot of a pull down experiment with
biotinylated Sclerostin mutants C84AC142R, DLoop and WT Sclerostin.
Sclerostin proteins were incubated with purified human LRP6 protein
fragment comprising propeller domains E1 and E2 (LRP6E1E2). For pull
down of protein complexes streptavidin-agarose beads were used.
Input: Samples before beads were added, beads: Beads after incubation
and washing. Proteins were detected using an antibody specific for the
His6-tag of the proteins. One representative out of four experiments is
shown.
doi:10.1371/journal.pone.0081710.g004
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Figure 5. Modeling of a Sclerostin-LRP6E1E2 complex indicates additional interactions apart from the NXI motif. (A) Interaction
scheme of a 7 mer peptide representing the loop tip amino acid sequence of Sclerostin (residues Leu90 to Arg96) bound into the cleft of the b-
propeller domain 1 of LRP6 (PDB entry 3SOV, [27]). Two main binding determinants were identified in the Sclerostin-derived peptide, Asn92 and Ile94,
which are engaged in several polar bonds (Asn92) as well as hydrophobic interactions (Ile94) to facilitate recognition and binding. Residues of LRP6
involved in the interaction with Asn92 and Ile94 are shown in the magnification on the left. (B) Theoretical model of the structured core domain of
Sclerostin docked onto the propeller 1-2 fragment of LRP6. The two cavities formed by propeller domain 1 and 2 are separated by 50 Å. The extended
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LRP6-peptide complexes [27] and the low inhibition efficiency
(IC50 between 10 to 30 mM) for 7 mer peptides comprising the
NXI-motif [27,43] indicate that additional interactions between
full-length Sclerostin and LRP6 exist. A detailed analysis of
Sclerostin binding to individual LRP6 propeller domains revealed
an affinity of about 60 nM for the first and a binding constant of
1.3 mM to the second propeller domain of LRP6 [27] suggesting
that elements outside the NXI-motif likely interact with propeller
2. However, the analyses of Holdsworth et al. and Veverka et al.
did not identify additional residues around the NXI-motif that
strongly influence Sclerostin-mediated inhibition of Wnt1 activity
[40,43]. The larger loss of Wnt1 inhibition observed for our
Sclerostin multi-variants DLoop and Alaloop, which contain a
truncated or scrambled loop region (Leu90 to Asn103), compared
to single point mutants N92A and I94A (multi-variants showed a
4-times higher IC50 value) might result from additional small
contributions of residues close by the NXI motif or elsewhere in
the loop. Also, the remaining Wnt inhibition capabilities of the
loop variants DLoop and Alaloop (see Fig. 2C) are a clear
indication for additional, albeit weak interactions outside the
investigated loop segment of Sclerostin and the LRP co-receptors.
A simple and naı̈ve model of a Sclerostin-LRP6E1E2 complex can
be build by first docking the structures of free Sclerostin [28,40]
and the complex of the Sclerostin peptide bound to LRP6E1 [27]
and then replacing the structure of the single propeller domain by
a structure of LRP6E1E2 [62]. Due to the elongated Sclerostin
architecture - the finger tips and the loop span about 45 to 55 Å -
contacts between Sclerostin and both propeller domains of
LRP6E1E2 are easily possible as the pockets of both propellers
are also 50 to 55 Å apart from each other (Fig. 5B). The high
flexibility and the various conformations of the loop region as seen
in the NMR structures of Sclerostin make this model rather
preliminary and don’t provide conclusive ideas about additional
epitopes [28,40]. But given the large diameter of the LRP
propeller 1 and the extended conformation the Sclerostin loop can
adopt, it seems a reasonable assumption that the flexible loop and/
or the central region of Sclerostin share additional contact(s) with
the rim of the LRP6 propeller 1 in a fashion similar to what is seen
in structure of the extended Laminin E1 module bound to the
propeller of Nidogen [65].
Our study now indeed identified the cystin-knot as a potentially
LRP6-interacting element in Sclerostin. Although the original
mutation C142R found in a Turkish patient suffering from
Sclerosteosis possibly acts through a gene-dosage effect resulting
from a diminished secretion of the variant protein [42], we were
interested whether this mutation might also have a direct
functional impact on LRP binding and Sclerostin’s Wnt inhibition
capabilities. Instead of using the original mutation we employed
the double variant C84AC142R to avoid low protein yield or
misfolding caused by the free thiol group of the unpaired cysteine.
The Sclerostin variant, which lacks the third disulfide of the
cystine-knot and instead has a bulky charged side chain at position
142, exhibits a strongly decreased inhibition efficiency for Wnt1
although not as strong as the Sclerostin loop variants DLoop and
Alaloop. A pull-down analysis then showed that the binding of
Sclerostin C84AC142R to the ectodomain of LRP6 is indeed
impaired strongly indicating that Cys142 and/or the region
around the third disulfide bond of the cystine-knot is a second
epitope for LRP6 interaction. A further hint that parts outside the
NXI-motif are likely involved in LRP6 binding comes from the
NMR titration study performed by Holdsworth et al. [43]. The
authors showed that many chemical shifts of the residues located
in Sclerostin’s structured core are affected by binding to the
LPR6E1E2 fragment, which is due to the fact that the Sclerostin
core now exhibits the slow overall tumbling rate of the large
LRP6E1E2NSclerostin complex. Only the residues in the flexible
N- and C-termini of Sclerostin do not show massive line
broadening, as their motions within the highly dynamic termini
is not restricted. If only residues in the dynamic loop, i.e. the NXI-
motif, would be involved in LRP6E1E2 binding all NMR signals
from residues in Finger 1 and 2 of Sclerostin should still be
observable (a.k.a. show no line broadening) as was shown for the
NMR mapping study employing a Sclerostin-neutralizing Fab
antibody fragment [40]. A final point might come from sequence
analysis of Sclerostin and the related Wnt-inhibitor Wise [66],
which shows high sequence homology also outside the NXI-motif
and mapping onto the Sclerostin structure indeed indicates a
highly similar protein surface starting from the loop tip down to
finger 2 (Fig. 5C,D).
A mechanistically interesting aspect in our study is that the
different Sclerostin-mediated inhibition of the two Wnt factors
Wnt1 and Wnt3a, both of which are reported to signal via the
canonical Wnt/b-Catenin pathway, differs [67,68]. The teams of
Rami Hannoush and Mike Costa convincingly showed that the
different Wnt factors bind to different propeller domains of LRP6
[44,69]. Wnt3/Wnt3a bind to propellers 3–4, but not to the
LRP6E1E2 fragment, in contrast, Wnt9b binds to the first two
propeller domains but not to the LRP6E3E4 fragment showing
that these two Wnt factors utilize distinct and non-overlapping
epitopes on LRP6 [44]. Using neutralizing anti-LRP6 antibodies
specifically raised against LRP6E1E2 and LRP6E3E4 the
canonical Wnt factors could be grouped into two functional
groups with respect to their binding site on LRPs, with Wnt3/3a
employing propellers 3–4 and Wnt1/2/2a/6/8a/9a/9b/10b
interacting exclusively with propeller domains 1 and 2 [69]. Thus
Dkk1, which was shown to bind to the LRP6 propeller domains 1
and 3 can efficiently antagonize both Wnt groups via a competitive
binding inhibition mechanism [67,68]. For Sclerostin, however,
whose binding site is limited to the propeller 1 and 2 of LRPs
[25,27], one would assume that inhibition by this particular Wnt
modulator is limited to the group Wnt1/2/2a/6/8a/9a/9b/10b,
but the non-overlapping binding sites for Sclerostin and Wnt3/
Wnt3a should result in no inhibition at all against Wnt3/Wnt3a.
Conformingly, in our setup Sclerostin neutralizes Wnt1 activity
with a low IC50 of about 10 nM, which nicely correlates with the
reported binding affinity of Sclerostin to the LRP6 extracellular
domain [27]. The dose-response curve for the inhibition of Wnt1
by increasing concentrations of Sclerostin yields a Hill-coefficient
consistent with a competitive binding of Wnt1 and Sclerostin to
LRP6. Remarkably, Sclerostin is capable to also neutralize Wnt3a
activity, however, a half-maximal concentration (IC50) of about
200 to 250 nM of Sclerostin is required. Since a more than 20-fold
architecture of Sclerostin (coincidentally measuring also 50 Å in length) might therefore contact propeller domain 1 and 2 (the latter with parts of
Sclerostin finger 1 or 2) possibly explaining the higher binding affinity of Sclerostin to LRP6 fragments containing both propeller domains compared
to LRP6 propeller 1 alone. (C) Surface representation of murine Sclerostin (left and right presentation are rotated by 180u around the y-axis) color-
coded on the basis of an amino acid sequence alignment (D). The colors mark the level of amino acid identity/homology between Sclerostin and Wise
proteins of different organisms with red highlighting invariant residues, orange for exchanges by homologous amino acids, and light and dark blue
marking variable residue positions. (D) Sequence alignment of the core domain of Sclerostin and the related Wnt inhibitor Wise from different
species. Secondary structure, architectural elements and disulfide bond pattern (1,2,3 mark the cystine-knot forming disulfides) are indicated.
doi:10.1371/journal.pone.0081710.g005
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higher Sclerostin concentration is necessary to antagonize Wnt3a
in comparison to Wnt1, this might question whether Sclerostin is a
physiologically relevant Wnt3a inhibitor in vivo. Mechanistically
interesting, analysis of the dose-response curves revealed a Hill
coefficient for Wnt3a inhibition of five or even larger (see Fig. 3A),
which is characteristic for a non-competitive mechanism [70]. As
other studies have also shown that Sclerostin can inhibit Wnt3a in
vitro [24,26,28,40] we have to accept that Sclerostin is (at least
from a mechanistic point of view) a Wnt3a inhibitor even though
Sclerostin and Wnt3a do not exhibit overlapping binding sites on
LRP6 [26,27] and thus the inhibition cannot be explained by a
pure competition mechanism. In line with a different inhibition
mechanism for Wnt1 and Wnt3a our functional study also reveals
differences in Sclerostin inhibiting either Wnt1 or Wnt3a activity.
Although the loop region comprising residues Leu90 to Asn103
seems important for neutralizing Wnt activity of both Wnt factors,
the effects of other mutations in Sclerostin differed between Wnt1
and Wnt3a. While residues outside the loop except for Cys142 did
not influence inhibition of Wnt1 activity, mutations in finger 2,
variants F2mut and R118A (see also Fig. 3E; Fig. S1B) altered
Wnt3a inhibition without affecting binding to LRP6, which is
consistent with a non-competitive mechanism. Finally, a direct
hint that the mechanism by which Sclerostin inhibits Wnt1 and
Wnt3a differs mechanistically is seen from the measurements of
cytoplasmic b-Catenin levels via in cell Western analysis. The
SuperTopFlash reporter construct used in numerous reports to
study canonical Wnt/b-Catenin signaling [34] measures b-
Catenin translocation into the nucleus via expression of the
reporter gene luciferase, which is under the control of a TCF/
LEF-promoter. In the absence of Wnt, b-Catenin is phosphory-
lated by a complex comprising GSK3, Axin and APC and is
destined for proteasomal degradation. In the presence of Wnt
phosphorylation of b-Catenin is abolished and the accumulating
b-Catenin is translocating from the cytoplasm into the nucleus
where it acts as transcriptional coactivator. Thus a dose-dependent
decrease in expression of the luciferase reporter upon inhibition of
either Wnt1 or Wnt3a by a Wnt antagonist protein suggests an
identical underlying mechanism for both Wnt factors leading to
proteasomal degradation of cytoplasmic b-Catenin and thus a
subsequent lack of transcriptional activation due to lower b-
Catenin levels in the nucleus. For the Wnt modulator Dkk1 this
holds true as the decrease in the reporter gene measurements
correlates with a decrease in b-Catenin concentration (see also
Fig. 3D). However, in the case of Sclerostin the level of
intracellular b-Catenin were only decreased, when Wnt1 was
antagonized by Sclerostin (similar to Dkk1), but for Wnt3a,
inhibition by Sclerostin even led to an increase in cytoplasmic b-
Catenin. Thus, whereas Sclerostin-mediated down-regulation of
Wnt1 activity is indeed due to degradation of b-Catenin, inhibition
of Wnt3a activity by Sclerostin is probably caused by an impaired
or blocked nuclear import of b-Catenin.
In summary, these observations point towards a more complex
regulatory mechanism by which Sclerostin modulates the activities
of different Wnt factors. A molecular scheme by which the Wnt
antagonists Dkk1 and Sclerostin inhibit activation of the b-Catenin
canonical signaling pathway exclusively by competing for the
shared receptor LRP5/6 does not sufficiently explain all inhibitory
activities of Sclerostin. There have been reports about Wnt-
induced LRP aggregation/oligomerization [71,72] as possible part
of Wnt receptor activation and antibody-mediated artificial
dimerization of LRP6 potentiated Wnt activity [69]. The
antagonist-LRP interaction could besides directly competing with
the Wnt-LRP interaction alter this oligomerization and thus
modulate the signaling state of the LRP co-receptor. The structure
analyses of the Dkk1 C-terminal domain bound to LRP6E3E4
revealed a second interaction site, which is too large to be solely
explained by crystal-lattice contacts and leads to a dimerized
LRP6 [60,62]. The physiological significance of this interaction is
yet unclear, as mutagenesis of residues in this second interface did
not alter the Dkk1-mediated inhibition of Wnt3a activity in a Wnt
reporter assay [62]. However, this might be misleading, as
Sclerostin also showed inhibition of Wnt1 and Wnt3a in a similar
Wnt reporter assay, but analysis of the b-Catenin levels clearly
suggest a different mechanism. Finally, low-resolution structure
studies of the full-length extracellular domain of LRP6 showing
the ectodomain as a dynamic architecture with the propellers 1–2
and 3–4 connected by a flexible hinge were already used to explain
simultaneous binding of full-length Dkk1 to propellers 1 and 3
[61,62]. Modeling suggests that the LRP ectodomain can adopt an
arc-like curvature [43] bringing the first and the last two propeller
domains in close proximity thereby also bringing Dkk1 and
Sclerostin into close proximity with all domains of LRP5/6 when
bound (Fig. S4). Thus activation by Wnt factors as well as their
inhibition by Sclerostin or Dkk family members might involve an
allosteric conformational switch in the LRP ectodomain as
suggested [71,72,73] possibly explaining how Sclerostin can
inhibit Wnt3a without sharing common binding epitopes on
LRP6. The data suggest that activation and inhibition of the
canonical Wnt/b-Catenin pathway is much more complex and
requires further structural and functional analyses.
Supporting Information
Figure S1 Surface plasmon resonance analysis using a
conformation sensitive Fab-fragment and additional
reporter gene data of Sclerostin mutants. (A) A sensogram
of the interaction of the antibody AbD10723 and either Sclerostin
WT or Sclerostin DLoop, the latter of which were immobilized on
the surface of a ProteOnTM GLC sensor chip, is shown. At time
point zero the antibody was perfused for 200 seconds. Dissociation
was initiated by injecting only running buffer and monitoring the
dissociation for 250 seconds. Binding affinities (KD) obtained by
fitting each binding curve using a Langmuir type 1:1 interaction
model (ProteOnTM Manager 3.0 software (BioRad)) are indicated.
(B) Reporter gene assay employing HEK293TSA cells stably
transfected with the Wnt-responsible luciferase reporter construct
SuperTOPFlash and stimulated with 1.5 nM recombinant
mWnt3a and serial dilutions of Sclerostin WT or the indicated
variants.
(TIF)
Figure S2 Binding of Sclerostin variants to LRP6 in
radioligand binding and pulldown assays. (A) COS1-cells
were transfected with hLRP6 and were incubated with I125-labeled
Sclerostin variants (I125). Cell-bound protein was chemically
crosslinked in the presence of different amounts of unlabeled
wildtype Sclerostin or unlabeled Sclerostin finger 2 multi-variant
F2mut (Comp. x fold) and analyzed by autoradiography. (B)
Longer exposure time for the Western Blot of pull down
experiment using the biotinylated Sclerostin mutants
C84AC142R, DLoop and WT Sclerostin (compare Fig. 4C).
(TIF)
Figure S3 Sequence alignment of the N-terminal pro-
peller domain of LRP5 and 6 (LRP5E1 and LRP6E1) with
the equivalent propeller domains of LRP4 and LDLR.
Whereas LRP4, 5, and 6 are known to bind Sclerostin, LDLR was
shown to not interact with the Wnt inhibitor. The sequence
alignment reveals that the asparagine residue of the NXI motif
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observed in the LRP6E1:Sclerostin peptide structure (PDB entry
3SOV, [27]) can be similarly accommodated as the structural
environment in the propeller domains is identical (contact residues
are indicated by NXI with bold letter for N). However, contact
residues for the interaction with the isoleucine residue of the NXI
motif differ (marked by NXI with bold letter I), in particular the
hydrophobic residues Trp255 and Met282 are replaced by smaller
or charged residues (Ile602 and Glu629, respectively) thereby
likely preventing binding of the Sclerostin NXI motif to LDLR.
(TIF)
Figure S4 Modeling suggests an arc like curvature of
the LRP6 ectodomaine. (A) Model of the extracellular domain
of LRP6 comprising all four propeller domains (LRP6E1E4). The
model was built by assembling the four propeller architecture by
structurally super-imposing the first propeller of one LRP6E1E2
moiety (molecule 1) (PDB entry 3S94) onto the second propeller
domain of a second LRP6E1E2 moiety (molecule 2) (for assembly
see B). This intermediate overlay was then used to structurally
align propeller 3 of a LRP6E3E4 fragment (PDB entry 3S8Z) onto
the second propeller of the realigned LRP6E1E2 molecule
(molecule 1) and connecting the LPR6E1E2 (molecule 2) and
the LRP6E3E4 fragment to provide the curved architecture for
the extracellular domain of LRP6E1E4. As the linker sequences
between each of the propeller domains share a similar length and
amino acid composition (see sequence alignment) the arc-like
architecture observed in low resolution structure studies [61,62] is
likely a consequence of the propeller 2 and 3 adopting a similar
interaction/conformation as observed in the LRP6 fragment
structures 1–2 and 3–4, which have been considered to form
rather rigid 2-propeller architectures. Analysis of the model
consisting of the full-length extracellular domain and particular
the modeled linker region between propeller 2 and 3 using rigid
body analysis, e.g. PiSQRD, http://pisqrd.escience-lab.org and
HingeProt, http://bioinfo3d.cs.tau.ac.il/HingeProt/have not re-
vealed a different mobility for the three linker regions. Thus
conformational rearrangement of the LRP6 architecture might be
due to individual rigid body movements of either one of the four
propeller domains. The curved assembly observed in the low-
resolution studies might be stabilized by similar hydrogen bond
connections between the individual propellers. The ‘‘inter-
propeller’’ hydrogen bonds observed (C, E) or predicted (D) are
shown with the linker region at the end of one EGF-like domain to
the beginning of the next YWTD domain marked in red.
(TIF)
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